Jack E. Ansell, MD, an internationally recognized expert in hemostasis and thrombosis, has been appointed the Michael S. Bruno, MD, Chairman of Medicine at Lenox Hill Hospital, effective February 6.
Dr. Ansell comes to Lenox Hill Hospital from Boston University Medical Center where he was Vice Chairman for Clinical Affairs of the Department of Medicine, interim Chief of Hematology/Oncology, and Professor of Medicine at Boston University School of Medicine.
Dr. Ansell earned his medical degree from the University of Virginia School of Medicine in 1972. His post-graduate training included a medical residency at Tufts New England Medical Center in Boston and fellowships in Hematology at Boston University and in Hematology/Hemostasis at Boston’s Veterans Administration Hospital
“Dr. Ansell’s outstanding credentials as a physician and leader, and his commitment to excellence in patient care, medical education and research support the mission, vision and values for which the Lenox Hill Hospital is known,” said Gladys George, President and CEO.
Dr. Ansell is the author of more than 200 publications including original research, reviews, editorials, chapters, and books. He serves as an associate editor for the Journal of Thrombosis and Thrombolysis and Current Clinical Pharmacology and as an editorial consultant for professional journals including The New England Journal of Medicine, Blood, Journal of Thrombosis and Haemostasis, and Circulation.
Dr. Ansell is the founder and immediate past Chair of the Anticoagulation Forum, a network of anticoagulation clinics throughout North America, and is a member of professional organizations including the American College of Physicians (Fellow), the American Society of Hematology, the International Society of Thrombosis and Hemostasis, the American Heart Association (Fellow), and the American Medical Association. He is Chair of two consensus committees of the American College of Chest Physicians working to establishing national guidelines on antithrombotic therapy.
Dr. Ansell’s main areas of research focus on the clinical problems of thrombosis, thrombotic disorders, and antithrombotic therapy. He has had a continued involvement in the application of new modes of delivering and monitoring anticoagulants, particularly in the management of oral anticoagulant therapy and has been increasingly involved in the clinical study of new oral anticoagulants.